-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DM-CHOC-PEN in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-CHOC-PEN in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-CHOC-PEN in Breast Cancer Drug Details: DM-CHOC-PEN is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DM-CHOC-PEN in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-CHOC-PEN in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-CHOC-PEN in Non-Small Cell Lung Cancer Drug Details: DM-CHOC-PEN is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-5167 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-5167 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-5167 in Solid Tumor Drug Details: DM-5167 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-199 in Vascular Dementias
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-199 in Vascular Dementias report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Vascular Dementias Drug Details: DM-199 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-199 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-199 in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Acute Ischemic Stroke Drug Details: DM-199 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-199 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-199 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-199 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval Analysis for Diabetic Complications
Overview How likely is it that the drugs in Diabetic Complications will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diabetic Complications Overview Diabetes is a chronic autoimmune disease if untreated or...
-
Product Insights
NewNet Present Value Model: DiaMedica Therapeutics Inc’s DM-199
Empower your strategies with our Net Present Value Model: DiaMedica Therapeutics Inc's DM-199 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Systemic Sclerosis (Scleroderma) Drug Details: KYV-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Lupus Nephritis Drug Details: KYV-101 is under development for...